Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9773201 | 0.75 | SMN1; SMN2 (0.46) | BLMSMN1; SMN2TAAR1 | |
| SCHEMBL5674353 | 0.75 | SMN1; SMN2 (0.46) | BLMSMN1; SMN2TAAR1 | |
| SCHEMBL1858577 | 0.75 | SMN1; SMN2 (0.46) | BLMSMN1; SMN2TAAR1 | |
| SCHEMBL8935817 | 0.73 | CASP3 (0.48) | BLMALDH1A1KDM4ESMN1; SMN2CA1 | |
| SCHEMBL7425913 | 0.71 | PPARG (0.50) | BLMMMP7 | |
| SCHEMBL6515182 | 0.71 | PPARG (0.50) | BLMMMP7 | |
| SCHEMBL20607556 | 0.71 | PPARG (0.40) | TSHRALDH1A1SMN1; SMN2MMP12POLB | |
| SCHEMBL1030314 | 0.71 | PPARG (0.40) | TSHRALDH1A1SMN1; SMN2MMP12POLB | |
| SCHEMBL10680554 | 0.71 | CTSK (0.43) | TSHRALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7728941 | 0.70 | MEN1 (0.43) | BLMTSHRALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633329-B2 | Method for preparing lisinopril intermediate | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633329-B2 | Method for preparing lisinopril intermediate | PKLR, PHYKPL, ACE | BLM 3111/4885TSHR 3518/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.